Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients

References

• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020 Apr 28;323(16):1574–1581.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Angeli F, Marazzato J, Verdecchia P, et al. Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19. Eur J Intern Med. 2021 Apr 19;89:81–86.
   PubMed Web of Science ®Google Scholar
• Angeli F, Spanevello A, De Ponti R, et al. Electrocardiographic features of patients with COVID-19 pneumonia. Eur J Intern Med. 2020 Aug;78:101–106.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Science Brief: evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. [ cited 2021 May 15]. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html
   Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the New York City Area. JAMA. 2020 Apr 22;323(20):2052.
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91–95.
   PubMed Web of Science ®Google Scholar
• Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020 Apr 30;130(4):304–309.
   PubMedGoogle Scholar
• Ran J, Song Y, Zhuang Z, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020 Nov;43(11):1267–1276.
   PubMed Web of Science ®Google Scholar
• Saeed S, Tadic M, Larsen TH, et al. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens. 2021 Jul 1;39(7):1282–1292.
   PubMed Web of Science ®Google Scholar
• Haynes RB, Kastner M, Wilczynski NL, et al. Developing optimal search strategies for detecting clinically sound and relevant causation studies in EMBASE. BMC Med Inform Decis Mak. 2005 Mar;22(5):8.
   Google Scholar
• McAuley L, Pham B, Tugwell P, et al. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000 Oct 7;356(9237):1228–1231.
   PubMed Web of Science ®Google Scholar
• Van Den Born BH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37–46.
   PubMed Web of Science ®Google Scholar
• Amraoui F, Van Der Hoeven NV, Van Valkengoed IG, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich). 2014 Feb;16(2):122–126.
   PubMed Web of Science ®Google Scholar
• Shantsila A, Shantsila E, Beevers DG, et al. Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant hypertension registry. J Hypertens. 2017 Nov;35(11):2310–2314.
   PubMed Web of Science ®Google Scholar
• Angeli E, Verdecchia P, Narducci P, et al. Additive value of standard ECG for the risk prediction of hypertensive disorders during pregnancy. Hypertens Res. 2011 Jun;34(6):707–713.
   PubMed Web of Science ®Google Scholar
• Angeli F, Angeli E, Reboldi G, et al. Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens. 2011 Dec;29(12):2320–2323.
   PubMed Web of Science ®Google Scholar
• Angeli F, Angeli E, Verdecchia P. Electrocardiographic changes in hypertensive disorders of pregnancy. Hypertens Res. 2014 Nov;37(11):973–975.
   PubMed Web of Science ®Google Scholar
• Angeli F, Angeli E, Verdecchia P. Novel electrocardiographic patterns for the prediction of hypertensive disorders of pregnancy–from pathophysiology to practical implications. Int J Mol Sci. 2015 Aug 7;16(8):18454–18473.
   PubMed Web of Science ®Google Scholar
• Angeli F, Reboldi G, Verdecchia P. Hypertensive urgencies and emergencies: misconceptions and pitfalls. Eur J Intern Med. 2020 Jan;71:15–17.
   PubMed Web of Science ®Google Scholar
• Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med. 1985 Dec;3(6 Suppl):10–15.
   PubMed Web of Science ®Google Scholar
• Derhaschnig U, Testori C, Riedmueller E, et al. Hypertensive emergencies are associated with elevated markers of inflammation, coagulation, platelet activation and fibrinolysis. J Hum Hypertens. 2013 Jun;27(6):368–373.
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000 Jul 29;356(9227):411–417.
   PubMed Web of Science ®Google Scholar
• Lowenstein CJ, Solomon SD. Severe COVID-19 Is a microvascular disease. Circulation. 2020 Oct 27;142(17):1609–1611.
   PubMed Web of Science ®Google Scholar
• Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020 Sep 1;41(32):3038–3044.
   PubMed Web of Science ®Google Scholar
• Chen R, Lan Z, Ye J, et al. Cytokine storm: the primary determinant for the pathophysiological evolution of covid-19 deterioration. Front Immunol. 2021;12:589095.
   PubMed Web of Science ®Google Scholar
• Coperchini F, Chiovato L, Rotondi M. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: not one for all but all for one! Front Immunol. 2021;12:668507.
   PubMed Web of Science ®Google Scholar
• Gursoy B, Surmeli CD, Alkan M, et al. Cytokine storm in severe COVID-19 pneumonia. J Med Virol. 2021 May 8;93(9):5474–5480.
   PubMed Web of Science ®Google Scholar
• Rabaan AA, Al-Ahmed SH, and Muhammad J, et al. Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines (Basel). 2021 Apr 29;9(5):436. DOI:https://doi.org/10.3390/vaccines9050436.
   Google Scholar
• Verdecchia P, Cavallini C, Spanevello A, et al. COVID-19: ACE2centric infective disease? Hypertension. 2020 Aug;76(2):294–299.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Cavallini C, Spanevello A, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020 Jun;76:14–20.
   PubMed Web of Science ®Google Scholar
• Angeli F, Reboldi G, Verdecchia P. Ageing, ACE2 deficiency and bad outcome in COVID-19. Clin Chem Lab Med. 2021 Jun 14;59(10):1607–1609.
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Reboldi G. RAAS Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Nov 12;383(20):1990–1991.
   PubMedGoogle Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586–590.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Cavallini C, et al. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]. G Ital Cardiol (Rome). 2020 May;21(5):321–327.
   PubMedGoogle Scholar
• Verdecchia P, Angeli F, and Reboldi G. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. J Hypertens. 2020;38(6):1190-1191. DOI:https://doi.org/10.1097/HJH.0000000000002469.
   Google Scholar
• Tang Q, Wang Y, Ou L, et al. Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation. Int J Biol Sci. 2021;17(8):1925–1939.
   PubMed Web of Science ®Google Scholar
• Lecarpentier Y, Vallee A. The key role of the level of ACE2 gene expression in SARS-CoV-2 infection. Aging (Albany NY). 2021 Jun 11;13(11):14552–14556.
   PubMedGoogle Scholar
• Bandara S, Ruwanpathirana A, Nagodawithana D, et al. Hypertensive Crisis in Pregnancy with COVID19: confirmed with rt-PCR for Nasopharyngeal Swab. Case Rep Obstet Gynecol. 2020;2020:8868952.
   PubMedGoogle Scholar
• Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis. 2006 Mar-Apr;48(5):316–325.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344–e418.
   PubMed Web of Science ®Google Scholar
• Li JZ, Eagle KA, Vaishnava P. Hypertensive and acute aortic syndromes. Cardiol Clin. 2013 Nov;31(4):493–501, vii.
   PubMed Web of Science ®Google Scholar
• Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral Hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032–2060.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334–1357.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982–1004.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liu D, Zeng S, et al. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension. J Infect. 2020 Nov;81(5):816–846.
   Web of Science ®Google Scholar
• Zhang LK, Sun Y, Zeng H, et al. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov. 2020 Dec 22;6(1):96.
   PubMed Web of Science ®Google Scholar
• Solaimanzadeh I. Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020 May 12;12(5):e8069.
   PubMed Web of Science ®Google Scholar
• Nouri-Vaskeh M, Kalami N, Zand R, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial. Int J Clin Pract. 2021 Jun;75(6):e14124.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Narkiewicz K, Burnier M, et al. Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Press. 2021 Feb;30(1):1–3.
   PubMed Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441–2448.
   PubMed Web of Science ®Google Scholar
• Pinto-Sietsma SJ, Flossdorf M, Buchholz VR, et al. Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):415–416.
   PubMed Web of Science ®Google Scholar
• Yan F, Huang F, Xu J, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020 Oct 29;6(1):77.
   PubMed Web of Science ®Google Scholar
• Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38(5):1–2. https://doi.org/10.1097/HJH.0000000000002450.
   PubMed Web of Science ®Google Scholar
• Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020 Apr 3;5(7):745.
   PubMed Web of Science ®Google Scholar
• Danser AHJ, Epstein M, Batlle D, et al. Renin-Angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers.Hypertension.2020Mar25;75(6):1382–1385. HYPERTENSIONAHA12015082
   PubMed Web of Science ®Google Scholar
• Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020 Mar 20;41(19):1801–1803.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, and Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671-1681.
   Web of Science ®Google Scholar
• Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020 May 1;382(26):2582.
   PubMed Web of Science ®Google Scholar
• Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 2;48:E004.
   Google Scholar
• Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020 Apr 23;5(7):825.
   PubMed Web of Science ®Google Scholar
• Yang G, Tan Z, Zhou L, et al. Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. Hypertension. 2020 Apr 29;76(1):51–58.
   PubMed Web of Science ®Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin-Angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020 May 1;382(25):2431–2440.
   PubMed Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 May 1;382(25):2441–2448.https://doi.org/10.1056/NEJMoa2008975
   PubMed Web of Science ®Google Scholar
• Mehta N, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting enzyme inhibitors and Angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 5;5(9):1020.
   PubMed Web of Science ®Google Scholar
• Conversano A, Melillo F, Napolano A, et al. RAAs inhibitors and outcome in patients with SARS-CoV-2 pneumonia. A case series study. Hypertension. 2020 May 8;76(2). https://doi.org/10.1161/HYPERTENSIONAHA.120.15312.
   Google Scholar
• Xue Y, Sun S, Cai J, et al. Effects of ACEI and ARB on COVID-19 patients: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320981321.
   Web of Science ®Google Scholar
• Baral R, Tsampasian V, Debski M, et al. Association Between Renin-Angiotensin-Aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Network Open. 2021 Mar 1;4(3):e213594.
   PubMed Web of Science ®Google Scholar
• Roubsanthisuk W, Wongsurin U, Buranakitjaroen P. Hypertensive emergencies remain a clinical problem and are associated with high mortality. J Med Assoc Thai. 2010 Jan;93(Suppl 1):S54–61.
   PubMedGoogle Scholar
• Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020 Aug 1;116(10):1688–1699.
   PubMed Web of Science ®Google Scholar
• Sharma RK, Stevens BR, Obukhov AG, et al. ACE2 (Angiotensin-Converting Enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2. Hypertension. 2020 Sep;76(3):651–661.
   PubMed Web of Science ®Google Scholar
• Angeli F, Masnaghetti S, Visca D, et al. Severity of COVID-19: the importance of being hypertensive. Monaldi Arch Chest Dis. 2020 May 20;90(2). https://doi.org/10.4081/monaldi.2020.1372.
   Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 May 24;111(20):2605–2610.
   PubMed Web of Science ®Google Scholar
• Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004 May;43(5):970–976.
   PubMed Web of Science ®Google Scholar
• Karram T, Abbasi A, Keidar S, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1351–8.
   PubMed Web of Science ®Google Scholar
• Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006 Oct;48(4):572–578.
   PubMed Web of Science ®Google Scholar
• Tsolaki V, Zakynthinos GE, Mantzarlis K, et al. Increased mortality among hypertensive COVID-19 patients: pay a closer look on diuretics in mechanically ventilated patients. Heart Lung. 2020 Nov - Dec;49(6):894–895.
   PubMed Web of Science ®Google Scholar